Clinical and Epidemiological Advantages of Culturing Bacterial Keratitis

Cornea

Volumn 23, Issue 1, 2004, Pages 38-42

  Wilhelmus, Kirk R ^a,c   Schlech, Barry A ^b  

^a CULLEN EYE INSTITUTE   (United States)

^b ALCON RESEARCH LTD   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bacterial keratitis; Corneal scraping; Corneal ulcer; Culture; Fluoroquinolone; Hypopyon; Metaanalysis; Metaregression

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEFAZOLIN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GENTAMICIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; CLINICAL TRIAL; COHORT ANALYSIS; CORNEA ULCER; EYE INFECTION; HUMAN; KERATITIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; BACTERIA; COHORT STUDIES; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; FLUOROQUINOLONES; HUMANS; KERATITIS; MULTICENTER STUDIES; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0348049458     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003226-200401000-00007     Document Type: Article

References (31)

1. McLeod SD, Kolahdouz-Isfahani A, Rostamian K, et al. The role of smears, cultures, and antibiotic susceptibility testing in the management of suspected infectious keratitis. Ophthalmology. 1996;103:23-28.
2. Levey SB, Katz HR, Abrams DA, et al. The role of cultures in the management of ulcerative keratitis. Cornea. 1997;16:383-386.
3. Rodman RC, Spisak S, Sugar A, et al. The utility of culturing corneal ulcers in a tertiary referral center versus a general ophthalmology clinic. Ophthalmology. 1997;104:1897-1901.
4. McDonnell PJ. Empirical or culture-guided therapy for microbial keratitis? A plea for data. Arch Ophthalmol. 1996;114:84-87.
5. Pepose JS, Wilhelmus KR. Divergent approaches to the management of corneal ulcers. Am J Ophthalmol. 1992;114:630-632.
6. McDonnell PJ, Nobe J, Gauderman WJ, et al. Community, care of corneal ulcers. Am J Ophthalmol. 1992;114:531-538.
7. McLeod SD, DeBacker CM, Viana MAG. Differential care of corneal ulcers in the community based on apparent severity. Ophthalmology. 1996;103:479-484.
8. Wilhelmus KR, Abshire RL, Schlech BA. The influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol. 2003 (in press).
9. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18:2693-2708.
10. O'Brien TP, Maguire MG, Fink NE, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995;113:1257-1265.
11. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ophthalmology. 1996;103:1854-1863.
12. Ofloxacin Study Group. Ofloxacin monotherapy for the primary treatment of microbial keratitis. A double-masked, randomized, controlled trial with conventional dual therapy. Ophthalmology. 1997;104:1902-1909.
13. Panda A, Ahuja R, Sastry SS. Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis. Eye. 1999;13:744-747.
14. Khokhar S, Sindhu N, Mirdha BR. Comparison of topical 0.3% ofloxacin to fortified tobramycincefazolin in the therapy of bacterial keratitis. Infection. 2000;28:149-152.
15. Kosrirukvongs P, Buranapongs W. Topical ciprofloxacin for bacterial corneal ulcer. J Med Assoc Thailand. 2000;93:776-782.
16. Prajna NV, George C, Selvaraj S, et al. Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis. Cornea. 2001;20:175-178.
17. Stein RM, Clinch TE, Cohen EJ, et al. Infected vs sterile corneal infiltrates in contact lens wearers. Am J Ophthalmol. 1988;105:632-636.
18. Forster RK. Conrad Berens lecture. The management of infectious keratitis as we approach the 21st century. CLAOJ. 1998;24:175-180.
19. Morlet N, Minassian D, Butcher J, et al. Risk factors for treatment outcome of suspected microbial keratitis. Br J Ophthalmol. 1999;83:1027-1031.
20. Greenland S. The effect of misclassification in the presence of covariates. Am J Epidemiol. 1980;112:564-569.
21. Piantadosi S. Clinical trials. A methodologic perspective. New York: John Wiley & Sons, 1997:375.
22. Sackett DL. The competing objectives of randomized trials. N Engl J Med. 1980;303:1059-1060.
23. Yusuf S. Strategies for patient recruitment into clinical trials. J Card Fail. 1998;4:235-236.
24. Hennekens CH, Buring JE. Validity versus generalizability, in clinical trial design and conduct. J Card Fail. 1998;4:239-241.
25. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20:637-648.
26. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106:1313-1318.
27. Kunimoto DY, Sharma S, Garg P, et al. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology. 1999;106:80-85.
28. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497-1502.
29. Tuft SJ, Matheson M. In vitro antibiotic resistance in bacterial keratitis in London. Br J Ophthalmol. 2000;84:687-691.
30. Tuft SJ. Suppurative keratitis. Br J Ophthalmol. 2003;87:127.
31. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-505.